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Background
The Step Study results generated volumes of press cover-
age. Complex results, with negative news of some vaccine
recipients being at higher risk of infection than similar
men who received placebo, might have created a negative
environment within the community that would be
recruited for future HIV vaccine studies. Focus groups in
four cities were convened to assess the current attitudes
and awareness of HIV vaccine research.
Methods
Seven groups were recruited through Craig's List and out-
reach through community-based organizations. Each of
the 66 participants was self-reported as an HIV uninfected
man who has sex with men and is between the age of 18
and 45. The same discussion guide was used for all seven
groups; progressing through word association with ''HIV''
and ''HIV vaccine,'' identifications of barriers and motiva-
tors to participation in clinical trials, and classification of
the trustworthiness of sources of information on clinical
trials.
Results
HIV vaccine was strongly associated with the word
''HOPE.'' The top barrier to participation is a fear of being
exposed to HIV from a belief that the vaccines contain the
HIV virus or that they would be expected to have unpro-
tected sex as part of the study. Other barriers were focused
on study related issues, e.g., side effects, duration of study.
The motivators for participation were highly related to
altruism or to an expected benefit to oneself. Personal
health care providers, community-based organizations
and local universities were trusted sources of information.
Religious leaders were distrusted as sources of informa-
tion on clinical trials. Governments and health insurers
were neutral to distrusted.
Conclusion
Recruitment for HIV vaccine trials must overcome low
public awareness of HIV vaccine research. Messages must
appeal to the altruistic motivators to participation and
address the barriers to participation that arise from lack of
knowledge about modern vaccine development and clin-
ical research.
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